Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia:: a proton magnetic resonance spectroscopy study

被引:56
|
作者
Sigmundsson, T
Maier, M
Toone, BK
Williams, SCR
Simmons, A
Greenwood, K
Ron, MA
机构
[1] UCL Hosp, Inst Neurol, Dept Neuropsychiat, London WC1N 3BG, England
[2] Kings Coll London, Inst Psychiat, Dept Psychol Med, London SE5 8AF, England
[3] Univ Hosp, Dept Psychiat, IS-101 Reykjavik, Iceland
[4] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Psychol Med, London W6 8RP, England
[5] Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London SE5 8AF, England
[6] Kings Coll London, Inst Psychiat, Dept Psychol, London SE5 8AF, England
关键词
frontal lobe; proton magnetic resonance spectroscopy ((1)H-MRS); schizophrenia; N-acetylaspartate (NAA); psychopathology;
D O I
10.1016/S0920-9964(02)00533-9
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction: Clinical, neuropsychological and functional neuroimaging studies in schizophrenia suggest impaired frontal lobe function, especially of the dorsolateral prefrontal region (DLPFR). This dysfunction has in particular been associated with negative or "deficit" symptoms. Despite these findings, morphological studies have failed to show consistent structural abnormalities in the frontal lobe. This may be because existing techniques are not sensitive enough to detect structural abnormalities or that dysfunction in the frontal lobe is caused by lesions elsewhere. We used volume-localised proton magnetic resonance spectroscopy ((1)H-MRS) to measure N-acetylaspartate (NAA), a neuronal marker, to evaluate the neuronal integrity of the dorsolateral prefrontal region in schizophrenic patients with persistent negative symptoms and in healthy comparison subjects. Method: Twenty-five patients who fulfilled DSM-IV criteria for schizophrenia and met the criteria for the Deficit syndrome were compared to 26 healthy controls matched for age and gender. Bilateral proton MR spectra were collected from a 2-cm(3) volume in the dorsolateral prefrontal region and the absolute concentrations of N-acetylaspartate, choline (Cho) and creatine + phosphocreatine (Cr + PCr) were measured. Results: There was a significant negative correlation between severity of symptoms and NAA concentration in the schizophrenic patients. This was more marked for positive symptoms and for general psychopathology than for negative symptoms. There was also a significant correlation between NAA concentration and social functioning within the schizophrenic group. There were no significant differences between the two groups for the three metabolites. Conclusions: The negative association between severity of symptoms and NAA in schizophrenic patients and an association of NAA with social functioning suggest that NAA may be an indicator of disease severity. The lack of significant mean difference in NAA between the two groups suggests that there is no marked neuronal loss in the dorsolateral prefrontal region in schizophrenia. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:63 / 71
页数:9
相关论文
共 50 条
  • [21] Proton magnetic resonance spectroscopy of the frontal, cingulate and perirolandic cortices and its relationship to skin conductance in patients with schizophrenia
    Sanches, R. F.
    Crippa, J. A. S.
    Hallak, J. E. C.
    de Sousa, J. P. M.
    Araujo, D.
    Santos, A. C.
    Zuardi, A. W.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2008, 41 (12) : 1132 - 1141
  • [22] Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia
    Deicken, RF
    Zhou, L
    Schuff, N
    Weiner, MW
    SCHIZOPHRENIA RESEARCH, 1997, 27 (01) : 65 - 71
  • [23] Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia
    Fujimoto, T
    Nakano, T
    Takano, T
    Takeuchi, K
    Yamada, K
    Fukuzako, T
    Akimoto, H
    BIOLOGICAL PSYCHIATRY, 1996, 40 (01) : 14 - 18
  • [24] Reduced Frontal Glutamate plus Glutamine and N-Acetylaspartate Levels in Patients With Chronic Schizophrenia but not in Those at Clinical High Risk for Psychosis or With First-Episode Schizophrenia
    Natsubori, Tatsunobu
    Inoue, Hideyuki
    Abe, Osamu
    Takano, Yosuke
    Iwashiro, Norichika
    Aoki, Yuta
    Koike, Shinsuke
    Yahata, Noriaki
    Katsura, Masaki
    Gonoi, Wataru
    Sasaki, Hiroki
    Takao, Hidemasa
    Kasai, Kiyoto
    Yamasue, Hidenori
    SCHIZOPHRENIA BULLETIN, 2014, 40 (05) : 1128 - 1139
  • [25] Proton magnetic resonance spectroscopy of lenticular nuclei in simple schizophrenia
    Ohara, K
    Isoda, H
    Suzuki, Y
    Takehara, Y
    Ochiai, M
    Takeda, H
    Hattori, K
    Igarashi, Y
    Ohara, K
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2000, 24 (04) : 507 - 519
  • [26] Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia-A Systematic Review and Meta-Analysis
    Brugger, Stefan
    Davis, John M.
    Leucht, Stefan
    Stone, James M.
    BIOLOGICAL PSYCHIATRY, 2011, 69 (05) : 495 - 503
  • [27] Hippocampal age-related changes in schizophrenia: A proton magnetic resonance spectroscopy study
    Maier, M
    Ron, MA
    SCHIZOPHRENIA RESEARCH, 1996, 22 (01) : 5 - 17
  • [28] H-1-MAGNETIC RESONANCE SPECTROSCOPY OF THE LEFT TEMPORAL AND FRONTAL LOBES IN SCHIZOPHRENIA - CLINICAL, NEURODEVELOPMENTAL, AND COGNITIVE CORRELATES
    BUCKLEY, PF
    MOORE, C
    LONG, H
    LARKIN, C
    THOMPSON, P
    MULVANY, F
    REDMOND, O
    STACK, JP
    ENNIS, JT
    WADDINGTON, JL
    BIOLOGICAL PSYCHIATRY, 1994, 36 (12) : 792 - 800
  • [29] Neuroprotective Effect of Modified Electroconvulsive Therapy for Schizophrenia A Proton Magnetic Resonance Spectroscopy Study
    Gan, Jing-Li
    Duan, Hui-Feng
    Cheng, Zheng-Xiang
    Yang, Jia-Ming
    Zhu, Xi-Quan
    Gao, Cun-You
    Zhao, Lan-Min
    Liang, Xue-Jun
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2017, 205 (06) : 480 - 486
  • [30] (31)PHOSPHORUS MAGNETIC-RESONANCE SPECTROSCOPY OF THE FRONTAL AND PARIETAL LOBES IN CHRONIC-SCHIZOPHRENIA
    DEICKEN, RF
    CALABRESE, G
    MERRIN, EL
    MEYERHOFF, DJ
    DILLON, WP
    WEINER, MW
    FEIN, G
    BIOLOGICAL PSYCHIATRY, 1994, 36 (08) : 503 - 510